163 related articles for article (PubMed ID: 29872694)
1. Clinical and radiographic response following targeting of BCAN-NTRK1 fusion in glioneuronal tumor.
Alvarez-Breckenridge C; Miller JJ; Nayyar N; Gill CM; Kaneb A; D'Andrea M; Le LP; Lee J; Cheng J; Zheng Z; Butler WE; Multani P; Chow Maneval E; Ha Paek S; Toyota BD; Dias-Santagata D; Santagata S; Romero J; Shaw AT; Farago AF; Yip S; Cahill DP; Batchelor TT; Iafrate AJ; Brastianos PK
NPJ Precis Oncol; 2017; 1(1):5. PubMed ID: 29872694
[TBL] [Abstract][Full Text] [Related]
2. Glioneuronal tumor with ATRX alteration, kinase fusion and anaplastic features (GTAKA): a molecularly distinct brain tumor type with recurrent NTRK gene fusions.
Bogumil H; Sill M; Schrimpf D; Ismer B; Blume C; Rahmanzade R; Hinz F; Cherkezov A; Banan R; Friedel D; Reuss DE; Selt F; Ecker J; Milde T; Pajtler KW; Schittenhelm J; Hench J; Frank S; Boldt HB; Kristensen BW; Scheie D; Melchior LC; Olesen V; Sehested A; Boué DR; Abdullaev Z; Satgunaseelan L; Kurth I; Seidlitz A; White CL; Ng HK; Shi ZF; Haberler C; Deckert M; Timmer M; Goldbrunner R; Tauziède-Espariat A; Varlet P; Brandner S; Alexandrescu S; Snuderl M; Aldape K; Korshunov A; Witt O; Herold-Mende C; Unterberg A; Wick W; Pfister SM; von Deimling A; Jones DTW; Sahm F; Sievers P
Acta Neuropathol; 2023 May; 145(5):667-680. PubMed ID: 36933012
[TBL] [Abstract][Full Text] [Related]
3. Larotrectinib in NTRK Fusion-Positive High-Grade Glioneuronal Tumor: A Case Report.
Tadipatri R; Eschbacher J; Fonkem E; Kresl J; Azadi A
Cureus; 2022 Nov; 14(11):e31449. PubMed ID: 36523718
[TBL] [Abstract][Full Text] [Related]
4. Identification and characterization of a novel
Milione M; Ardini E; Christiansen J; Valtorta E; Veronese S; Bosotti R; Pellegrinelli A; Testi A; Pietrantonio F; Fucà G; Wei G; Murphy D; Siena S; Isacchi A; De Braud F
Oncotarget; 2017 Aug; 8(33):55353-55360. PubMed ID: 28903424
[TBL] [Abstract][Full Text] [Related]
5. Activity of Entrectinib in a Patient With the First Reported
Sigal D; Tartar M; Xavier M; Bao F; Foley P; Luo D; Christiansen J; Hornby Z; Maneval EC; Multani P
J Natl Compr Canc Netw; 2017 Nov; 15(11):1317-1322. PubMed ID: 29118225
[TBL] [Abstract][Full Text] [Related]
6. Acral Lentiginous Melanoma Harboring a
Couts KL; McCoach CE; Murphy D; Christiansen J; Turner J; Lewis KD; Robinson WA; Doebele RC
JCO Precis Oncol; 2017 Nov; 1():1-7. PubMed ID: 35172482
[TBL] [Abstract][Full Text] [Related]
7. Anaplastic glioneuronal tumor with
Liu L; Narayan P; Xiong J; Xiong Z
Intractable Rare Dis Res; 2019 Nov; 8(4):279-282. PubMed ID: 31890457
[TBL] [Abstract][Full Text] [Related]
8. Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer.
Farago AF; Le LP; Zheng Z; Muzikansky A; Drilon A; Patel M; Bauer TM; Liu SV; Ou SH; Jackman D; Costa DB; Multani PS; Li GG; Hornby Z; Chow-Maneval E; Luo D; Lim JE; Iafrate AJ; Shaw AT
J Thorac Oncol; 2015 Dec; 10(12):1670-4. PubMed ID: 26565381
[TBL] [Abstract][Full Text] [Related]
9. TRK Inhibition: A New Tumor-Agnostic Treatment Strategy.
Kummar S; Lassen UN
Target Oncol; 2018 Oct; 13(5):545-556. PubMed ID: 30276762
[TBL] [Abstract][Full Text] [Related]
10. Targeting TRK family proteins in cancer.
Khotskaya YB; Holla VR; Farago AF; Mills Shaw KR; Meric-Bernstam F; Hong DS
Pharmacol Ther; 2017 May; 173():58-66. PubMed ID: 28174090
[TBL] [Abstract][Full Text] [Related]
11. Clinicopathologic Features of Non-Small-Cell Lung Cancer Harboring an
Farago AF; Taylor MS; Doebele RC; Zhu VW; Kummar S; Spira AI; Boyle TA; Haura EB; Arcila ME; Benayed R; Aisner DL; Horick NK; Lennerz JK; Le LP; Iafrate AJ; Ou SI; Shaw AT; Mino-Kenudson M; Drilon A
JCO Precis Oncol; 2018; 2018():. PubMed ID: 30215037
[TBL] [Abstract][Full Text] [Related]
12. Beyond
Farago AF; Azzoli CG
Transl Lung Cancer Res; 2017 Oct; 6(5):550-559. PubMed ID: 29114471
[TBL] [Abstract][Full Text] [Related]
13. ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer.
Pietrantonio F; Di Nicolantonio F; Schrock AB; Lee J; Tejpar S; Sartore-Bianchi A; Hechtman JF; Christiansen J; Novara L; Tebbutt N; Fucà G; Antoniotti C; Kim ST; Murphy D; Berenato R; Morano F; Sun J; Min B; Stephens PJ; Chen M; Lazzari L; Miller VA; Shoemaker R; Amatu A; Milione M; Ross JS; Siena S; Bardelli A; Ali SM; Falcone A; de Braud F; Cremolini C
J Natl Cancer Inst; 2017 Dec; 109(12):. PubMed ID: 29370427
[TBL] [Abstract][Full Text] [Related]
14. Merestinib (LY2801653) inhibits neurotrophic receptor kinase (NTRK) and suppresses growth of NTRK fusion bearing tumors.
Konicek BW; Capen AR; Credille KM; Ebert PJ; Falcon BL; Heady GL; Patel BKR; Peek VL; Stephens JR; Stewart JA; Stout SL; Timm DE; Um SL; Willard MD; Wulur IH; Zeng Y; Wang Y; Walgren RA; Betty Yan SC
Oncotarget; 2018 Mar; 9(17):13796-13806. PubMed ID: 29568395
[TBL] [Abstract][Full Text] [Related]
15. Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study.
Laetsch TW; DuBois SG; Mascarenhas L; Turpin B; Federman N; Albert CM; Nagasubramanian R; Davis JL; Rudzinski E; Feraco AM; Tuch BB; Ebata KT; Reynolds M; Smith S; Cruickshank S; Cox MC; Pappo AS; Hawkins DS
Lancet Oncol; 2018 May; 19(5):705-714. PubMed ID: 29606586
[TBL] [Abstract][Full Text] [Related]
16. Detection of Tumor NTRK Gene Fusions to Identify Patients Who May Benefit from Tyrosine Kinase (TRK) Inhibitor Therapy.
Hsiao SJ; Zehir A; Sireci AN; Aisner DL
J Mol Diagn; 2019 Jul; 21(4):553-571. PubMed ID: 31075511
[TBL] [Abstract][Full Text] [Related]
17. An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101.
Doebele RC; Davis LE; Vaishnavi A; Le AT; Estrada-Bernal A; Keysar S; Jimeno A; Varella-Garcia M; Aisner DL; Li Y; Stephens PJ; Morosini D; Tuch BB; Fernandes M; Nanda N; Low JA
Cancer Discov; 2015 Oct; 5(10):1049-57. PubMed ID: 26216294
[TBL] [Abstract][Full Text] [Related]
18. [Clinicopathological characteristics of NTRK-rearranged mesenchymal tumors in childhood].
Yin MZ; Ma J; He Q; Shen P; Chen JF; Jin XT; Zhang ZD; Kuick CH; Chen HY; Ng EHQ; Aw SJ; Chang KTE
Zhonghua Bing Li Xue Za Zhi; 2020 Jul; 49(7):675-680. PubMed ID: 32610377
[No Abstract] [Full Text] [Related]
19. Molecularly defined diffuse leptomeningeal glioneuronal tumor (DLGNT) comprises two subgroups with distinct clinical and genetic features.
Deng MY; Sill M; Chiang J; Schittenhelm J; Ebinger M; Schuhmann MU; Monoranu CM; Milde T; Wittmann A; Hartmann C; Sommer C; Paulus W; Gärtner J; Brück W; Rüdiger T; Leipold A; Jaunmuktane Z; Brandner S; Giangaspero F; Nozza P; Mora J; Morales la Madrid A; Cruz Martinez O; Hansford JR; Pietsch T; Tietze A; Hernáiz-Driever P; Stoler I; Capper D; Korshunov A; Ellison DW; von Deimling A; Pfister SM; Sahm F; Jones DTW
Acta Neuropathol; 2018 Aug; 136(2):239-253. PubMed ID: 29766299
[TBL] [Abstract][Full Text] [Related]
20. Somatic chromosomal engineering identifies BCAN-NTRK1 as a potent glioma driver and therapeutic target.
Cook PJ; Thomas R; Kannan R; de Leon ES; Drilon A; Rosenblum MK; Scaltriti M; Benezra R; Ventura A
Nat Commun; 2017 Jul; 8():15987. PubMed ID: 28695888
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]